X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Orphan Technologies' lead product OT-58 is a novel investigational human enzyme replacement therapy being evaluated in Phase 1/2 development for the treatment of classical homocystinuria.
Lead Product(s): OT-58
Therapeutic Area: Genetic Disease Product Name: OT-58
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Travere Therapeutics
Deal Size: $517.0 million Upfront Cash: $90.0 million
Deal Type: Acquisition November 12, 2020
Details:
Agreement adds OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria.
Lead Product(s): OT-58
Therapeutic Area: Genetic Disease Product Name: OT-58
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Travere Therapeutics
Deal Size: $517.0 million Upfront Cash: $90.0 million
Deal Type: Acquisition October 22, 2020
Details:
Orphan Technologies is now eligible to receive a priority review voucher that may be utilized for subsequent human drug applications.
Lead Product(s): OT-58
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
